ArticleCancer medicine2023

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers.

David Starks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.